dulaglutide + tofogliflozin

Dulaglutide + tofogliflozin is a combination therapy consisting of two antidiabetic agents used for the management of type 2 diabetes mellitus. Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that increases insulin secretion, decreases glucagon secretion, and slows gastric emptying in response to elevated blood glucose levels. Tofogliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces renal glucose reabsorption, leading to increased urinary glucose excretion and lower blood glucose levels. The combination offers complementary mechanisms resulting in improved glycemic control, weight reduction, and potential cardiovascular benefits compared to monotherapy with either agent alone[3][4][7]. This combination has been shown in clinical studies to provide additive effects on lowering HbA1c, body weight, and systolic blood pressure[3].